Literature DB >> 6626416

Acebutolol pharmacokinetics in renal failure.

R S Smith, D J Warren, A G Renwick, C F George.   

Abstract

Acebutolol was administered orally in a single dose of 200 mg to 17 individuals whose renal function varied markedly. The plasma half-life and elimination rate constant for acebutolol showed a four-fold variation but these did not correlate with the degree of renal impairment. However, there was a good correlation between the renal clearance of creatinine and that of acebutolol (P less than 0.001). The half-life and elimination rate of the acetyl metabolite, diacetolol, were subject to 10-fold inter-individual variability which correlated significantly with the creatinine clearance and serum creatinine concentration. The AUC for the acetyl metabolite showed a 40-fold individual variation which also correlated with renal function. It is concluded that renal elimination is the principal route of excretion for diacetolol but not the parent compound, acebutolol.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6626416      PMCID: PMC1427998          DOI: 10.1111/j.1365-2125.1983.tb02158.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  High-pressure liquid chromatographic analysis of drugs in biological fluids. V. Analysis of acebutolol and its major metabolite.

Authors:  P J Meffin; S R Harapat; Y G Yee; D C Harrison
Journal:  J Chromatogr       Date:  1977-08-01

2.  Elimination of drugs by active intestinal transport.

Authors:  C F George; B S Gruchy
Journal:  J Pharm Pharmacol       Date:  1979-09       Impact factor: 3.765

3.  Pharmacokinetics of acebutolol in patients with all grades of renal failure.

Authors:  A Roux; P Aubert; J Guedon; B Flouvat
Journal:  Eur J Clin Pharmacol       Date:  1980-05       Impact factor: 2.953

4.  Comparison of the antihypertensive and hormonal effects of a cardioselective beta-blocker, acebutolol, and diuretics in essential hypertension.

Authors:  F Alhenc-Gelas; P F Plouin; M B Ducrocq; P Corvol; J Menard
Journal:  Am J Med       Date:  1978-06       Impact factor: 4.965

5.  Acebutolol in the treatment of patients with hypertension and renal functional impairment.

Authors:  E Begg; S Munn; R R Bailey
Journal:  N Z Med J       Date:  1979-04-25

6.  Observations on the pharmacokinetics of acebutolol.

Authors:  C M Kaye; C R Kumana; M Leighton; J Hamer; P Turner
Journal:  Clin Pharmacol Ther       Date:  1976-04       Impact factor: 6.875

7.  A multicentre study of a once daily dosage of acebutolol in the treatment of hypertension in general practice.

Authors:  P G Baker; J Goulton
Journal:  J Int Med Res       Date:  1979       Impact factor: 1.671

8.  Acebutolol in hypertension--double-blind trial against placebo.

Authors:  M A Martin; C A Phillips; A J Smith
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

9.  Assessment of selective beta-adrenoceptor blockade in man.

Authors:  R H Briant; C T Dollery; T Fenyvesi; C F George
Journal:  Br J Pharmacol       Date:  1973-09       Impact factor: 8.739

10.  Plasma and urine concentrations of acebutolol and its acetyl metabolite in patients with renal functional impairment.

Authors:  S Munn; R R Bailey; E Begg; R Ebert; D G Ferry
Journal:  N Z Med J       Date:  1980-04-23
View more
  2 in total

Review 1.  Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications.

Authors:  A Ebihara; A Fujimura
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

2.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.